Paradoxical aspects of parkinsonian tremor

Movement Disorders

Volumn 23, Issue 2, 2008, Pages 168-173

  Fishman, Paul S ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

DBS; Parkinson's disease; Tremor

Indexed keywords

BENZATROPINE; BROMOCRIPTINE; BUDIPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; LEVODOPA; PERGOLIDE; PLACEBO; PRAMIPEXOLE; RADIOLIGAND; ROPINIROLE;

CORRELATION ANALYSIS; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; DRUG EFFICACY; HUMAN; IMAGING; LOW DRUG DOSE; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBTHALAMIC NUCLEUS; SURGICAL TECHNIQUE; THALAMUS;

ANTIPARKINSON AGENTS; ELECTRIC STIMULATION THERAPY; HUMANS; PARKINSON DISEASE; THALAMUS; TREMOR;

EID: 39749124177     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21736     Document Type: Review

References (78)

1. Calne DB, Stoessl AJ. Early Parkinsonism. Clin Neuropharmacol 1986;9 (Suppl 2):S3-S8.
2. Litvan I, Bhatia KP, Burn DJ, et al. Movement Disorders Society Scientific Issues Committee Report: SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders. Mov Disord 2003;18:467-486.
3. Dural A, Atay MB, Akbostanci C, Kucukdeveci A. Impairment, disability, and life satisfaction in Parkinson's disease. Disabil Rehabil 2003;25:318-323.
4. Zimmerman R, Deuschl G, Hornig A, Schulte-Monting J, Fuchs G, Lucking CH. Tremors in Parkinson's disease: symptom analysis and rating. Clin Neuropharmacol 1994;17:303-314.
5. Hallet M. Parkinson revisited: pathophysiology of motor signs. Adv Neurol 2003;91:19-28.
6. Joffroy AJ. Pathophysiology of parkinsonian tremor. N Engl J Med 1969;281:446-447.
7. Timmermann L, Gross J, Dirks M, Volkmann J, Freund HJ, Schnitzler A. The cerebral oscillatory network of parkinsonian resting tremor. Brain 2003;126 (Partt 1):199-212.
8. Koller WC. Pharmacologic treatment of parkinsonian tremor. Arch Neurol 1986;43:126-127.
9. Koller WC, Herbster G. Adjuvant therapy of parkinsonian tremor. Arch Neurol 1987;44:921-923.
10. Henderson JM, Yiannikas C, Morris JG, Einstein R, Jackson D, Byth K. Postural tremor of Parkinson's disease. Clin Neuropharmacol 1994;17:277-285.
11. Kraus PH, Lemke MR, Reichmann H. Kinetic tremor in Parkinson's disease - an underrated symptom. J Neural Transm 2006;113:845-853.
12. Pirker W. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it? Mov Disord 2003;18 (Suppl 7):S43-S51.
13. Benamer HT, Oertel WH, Patterson J, et al. Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders, part 1: baseline and 3-month observations. Mov Disord 2003;18:977-984.
14. Doder M, Rabiner EA, Turjanski N, Lees AJ, Brook DJ; 11C-WAY 100635 PET study. Tremor in Parkinson's disease and serotonergic dysfunction: an 11C-WAY 100635 PET study. Neurology 2003;60:601-605.
15. Louis ED, Tang MX, Cote L, Alfaro B, Mejia H, Marder K. Progression of parkinsonian signs in Parkinson disease. Arch Neurol 1999;56:334-337.
16. 123I] β-CIT SPECT study in early, nonmedicated patients. Mov Disord 2001;16:1033-1040.
17. Josephs KA, Matsumoto JY, Ahlskog JE. Benign tremulous Parkinsonism. Arch Neurol 2006;63:354-357.
18. Ghaemi M, Raethjen J, Hilker R, et al. Monosymptomatic resting tremor and Parkinson's disease: a multitracer P Positron emission tomographic study. Mov Disord 2002;17:782-788.
19. Brooks DJ, Playford ED, Ibanez V, et al. Isolated tremor and disruption of the nigrostriatal dopaminergic system: an 18F-dopa PET study. Neurology 1992;42:1554-1560.
20. Chaudhuri KR, Buxton-Thomas M, Dhawan V, Pen R, Meilak C, Brookes DJ. Long duration asymmetrical postural tremor is likely to predict development of Parkinson's disease and not essential tremor: clinical follow up study of 13 cases. J Neurol Neurosurg Psychiatry 2005;76:115-117.
21. Fahn S, Oakes D, Shoulson I, et al.; Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-2508.
22. Whone AL, Watts RL, Stoessl AJ, et al.; REAL-PET Study Group. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003;54:93-101.
23. Antonini A, Moeller JR, Nakamura T, Spetsieris P, Dhawan V, Eidelberg D. The metabolic anatomy of tremor in Parkinson's disease. Neurology 1998;51:803-810.
24. Eidelberg D, Moeller JR, Ishikawa T, et al. Assessment of disease severity in parkinsonism with fluorine-18-fiuorodeoxyglucose and PET. J Nucl Med 1995;36:378-383.
25. Lozza C, Marie RM, Baron JC. The metabolic substrates of bradykinesia and tremor in uncomplicated Parkinson's disease. Neuroimage 2002;17:688-699.
26. Lenz FA, Vitek JL, DeLong MR. Role of the thalamus in parkinsonian tremor: evidence from studies in patients and primate models. Stereotact Funct Neurosurg 1993;60:94-103.
27. Gonzalez-Alegre P. Monomelic parkinsonian tremor caused by contralateral substantia nigra stroke. Parkinsonism Relat Disord 2007;13:182-184.
28. Kulisevsky J, Berthier ML, Avila A, Roig C. Unilateral parkinsonism and stereotyped movements following a right lenticular infarction. Mov Disord 1996;11:752-754.
29. Krauss JK, Paduch T, Mundinger F, Seeger W. Parkinsonism and rest tremor secondary to supratentorial tumours sparing the basal ganglia. Acta Neurochir (Wien) 1995;133:22-29.
30. Lee MS, Lee SA, Heo JH, Choi IS. A patient with a resting tremor and a lacunar infarction at the border between the thalamus and the internal capsule. Mov Disord 1993;8:244-246.
31. Thanvi B, Lo N, Robinson T. Vascular Parkinsonism - an important cause of Parkinsonism in older people. Age Ageing 2005;34:114-119.
32. Carr J. Tremor in Parkinson's disease. Parkinsonism Relat Disord 2002;8:223-234.
33. Brumlik J, Canter G, LaTorre R, et al. A critical analysis of the affects of trihexiphnidyl (Artane) on the components of the parkinsonian syndrome. J Nerv Ment Dis 1964;138:424-431.
34. Doshay LJ. Five year study of benztropine (Cogentin)methane sulfonate. JAMA 1956;162:1031-1034.
35. Katzenschlager R, Sampaio C, Costa J, Lees A. Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst Rev 2003;2:CD003735.
36. Schrag A, Schelosky L, Scholz U, Poewe W. Reduction of Parkinsonian signs in patients with Parkinson's disease by dopaminergic versus anticholingergic single-dose challenges. Mov Disord 1999;14:252-255.
37. Navan P, Findley LJ, Jeffs JA, Pearce RK, Bain PG. Randomized, double-blind, 3-month parallel study of the effects pramipexole, pergolide, and placebo on parkinsonian tremor. Mov Disord 2003;18:1324-1331.
38. Elble RJ. Tremor and dopamine agonists. Neurology 2002;58 (4 Suppl 1):S57-S62.
39. Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson's disease. A randomized dose-ranging study. JAMA 1997;278:125-130.
40. Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group. Neurology 1997;49:1060-1065.
41. 4L Shannon KM, Bennett JP, Jr, Friedman JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group. Neurology 1997;49:724-728.
42. Adler Ch, Sethi KD, Hauser RA, et al. Ropinirole for the treatment of early Parkinson's disease. The Ropinorole Study Group. Neurology 1997;49:393-399.
43. Rascol O, Brooks DJ, Brunt ER, Korczyn AD, Poewe WH, Stocchi F. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group. Mov Disord 1998;13:39-45.
44. Schrag A, Keens J, Warner J; Ropinorole Study Group. Ropinirole for the treatment of tremor in early Parkinson's disease. Eur J Neurol 2002;9:253-257.
45. Pogarell O, Gasser T, van Hilten JJ, et al. Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomized, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry 2002;72:713-720.
46. Factor SA, Sanchez-Ramos JR, Weiner WJ. Parkinson's disease: an open label trial of pergolide in patients failing bromocriptine therapy. J Neurol Neurosurg Psychiatry 1988;51:529-533.
47. Olanow CW, Fahn S, Muenter M, et al. A multicenter double-blind placebo-controlled trial of pergolide adjunct to Sinemet in Parkinson's disease. Mov Disord 1994;9:40-47.
48. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of double-blind, placebo-controlled, parallel-group study. Neurology 1997;49:162-168.
49. Kunig G, Pogarell O, Moller JC, Delf M, Oertel WH. Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson's disease. Clin Neuropharmacol 1999;22:301-305.
50. Jansen EN. Clozapine in treatment of tremor in Parkinson's disease. Acta Neurol Scan 1995;89:262-265.
51. Bonucelli U, Cervolo R, Salvetti S, D'Avino C, Dell Dotto P, Rossi G, Murri L. Clozapine in Parkinson's disease tremor. Effects of acute and chronic administration. Neurology 1997;49:1587-1590.
52. Friedman JH, Koller WC, Lannon MC, Busenbark K, Swanson-Hyland E, Smith D. Benztropine versus clozapine for the treatment of tremor in Parkinson's disease. Neurology 1997;48:1077-1081.
53. Binder DK, Rau G, Starr PA. Hemorrhagic complications of microelectrode-guided deep brain stimulation. Stereotact Funct Neurosurg 2003;80:28-31.
54. Umemura A, Jaggi JL, Hurtig HI, et al. Deep brain stimulation for movement disorders: morbidity and mortality in 109 patients. J Neurosurg 2003;98:779-784.
55. Ma J, Alvir J, Lieberman A, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis - incidence and risk factors in the United States. N England J Med 1993;329:162-167.
56. Reichmann H. Budipine in Parkinson's tremor. J Neurol Sci 2006;248:53-55.
57. Jellinger K, Bliesath H. Adjuvant treatment of Parksinson's disease with budipine: a double-blind trial versus placebo. J Neurol 1987;234:280-282.
58. Przuntek H, Bittkau S, Bliesath H, et al. Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen. Arch Neurol 2002;59:803-806.
59. Spieker S, Loschmann P, Jentgens C, Boose A, Klockgether T, Dichgans J. Tremorlytic activity of budipine: a quantitative study with long-term tremor recordings. Clin Neuropharmacol 1995;18:266-272.
60. Spieker S, Eisebitt R, Breit S, et al. Tremorlytic activity of budipine in Parkinson's disease. Clin Neuropharmacol 1999;22:115-119.
61. Tasker RR. Deep brain stimulation is preferable to thalamotomy for tremor suppression. Surg Neurol 1998;49:145-153; discussion 153-154.
62. Ondo W, Jankovic J, Scwhartz K, Almaguer M, Simpson RK. Unilateral thalamic deep brain stimulation for refractory essential tremor and Parkinson's disease tremor. Neurology I998;51:1063-1069.
63. Koller WC, Lyons KE, Wilkinson SB, Troster AI, Pahwa R. Long-term safety and efficacy of unilateral deep brain stimulation of the thalamus in essential tremor. Mov Disord 2001;16:464-468.
64. Lyons KE, Koller WC, Wilkinson SB, Pahwa R. Long term safety and efficacy of unilateral deep brain stimulation of the thalamus for parkinsonian tremor. J Neurol Neurosurg Psychiatry 2001 ;71:682-684.
65. Rehncrona S, Johnels B, Widner H, Tornqvist AL, Hariz M, Sydow O. Long-term efficacy of thalamic deep brain stimulation for temor: double-blind assessments. Mov Disord 2003;18:163-170.
66. Deep-Brain Stimulation for Parkinson's Disease Study Group. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med 2001;345:956-963.
67. Putzke JD, Wharen RE, Jr, Wszolek ZK, Turk MF, Strongosky AJ, Uitti RJ. Thalamic deep brain stimulation for tremor-predominant Parkinson's disease. Parkinonism Relat Disord 2003;10:81-88.
68. Anderson VC, Burchiel KJ, Hogarth P, Favre J, Hammstad JP. Pallidal vs subthalamic nucleus deep brain stimulation in Parkinson disease. Arch Neurol 2005;62:554-560.
69. Rodriguez MC, Guridi OJ, Alvarez L, et al. The subthalamic nucleus and tremor in Parkinson's disease. Mov Disord 1998;13 (Suppl 3):111-118.
70. Krack P, Benazzouz A, Pollak P, et al. Treatment of tremor in Parkinson's disease by subthalamic nucleus stimulation. Mov Disord 1998;13:907-914.
71. Patel NK, Heywood P, O'Sullivan K, McCarter R, Love S, Gill SS. Unilateral subthalamotomy in the treatment of Parkinson's disease. Brain 2003;125 (Part 4):1136-1145.
72. Sturman MM, Vaillancourt DE, Metman LV, Bakay RA, Corcos DM. Effects of subthalamic nucleus stimulation and medication on resting and postural tremor in Parkinson's disease. Brain 2004;127 (Part 9):2131-2143.
73. Taha JM, Favre J, Baumann TK, Burchiel KJ. Tremor control after pallidotomy in patients with Parkinson's disease: correlation with microrecording findings. J Neurosurg 1977;86:642-647.
74. Vitek JL, Bakay AE, Freeman A, et al. Randomized trial of pallidotomy versus medical therapy for Parkinson's disease. Ann Neurol 2003;53:558-569.
75. Blahak C, Wohrle JC, Capelle HH, et al. Tremor reduction by subthalamic nucleus stimulation and medication in advanced Parkinson's disease. J Neurol 2007;254:169-178.
76. Fraix V, Pollak P, Moro E, et al. Subthalamic nucleus stimulation in tremor dominant parkinsonian patients with previous thalamic surgery. J Neurol Neurosurg Psychiatry 2005;76:246-248.
77. Plaha P, Patel NK, Gill SS. Stimulation of the subthalamic region for essential tremor. J Neurosurg 2004;101:48-54.
78. Terao T, Takahashi H, Yokochi F, Taniguchi M, Okiyama R, Hamada I. Hemorrhagic complication of stereotactic surgery in patients with movement disorders. J Neurosurg 2003;98:1241-1246.